quinin
first
recogn
potent
antimalari
agent
hundr
year
ago
sinc
benefici
effect
quinin
advanc
synthet
form
chloroquin
hydroxychloroquin
increasingli
recogn
myriad
diseas
addit
malaria
recent
year
antimalari
shown
variou
immunomodulatori
effect
current
establish
role
manag
rheumat
diseas
system
lupu
erythematosu
rheumatoid
arthriti
skin
diseas
treatment
chronic
q
fever
late
addit
metabol
cardiovascular
antithrombot
antineoplast
effect
antimalari
shown
review
discuss
known
variou
immunomodulatori
mechan
antimalari
current
evid
benefici
effect
variou
diseas
potenti
novel
applic
hydroxyl
group
decreas
toxic
conserv
efficaci
hydroxychloroquin
numer
known
immunomodulatori
effect
specif
mechan
individu
diseas
clear
major
propos
mechan
action
antimalari
immun
system
includ
interfer
lysosom
acidif
inhibit
proteolysi
chemotaxi
phagocytosi
antigen
present
decreas
macrophagemedi
cytokin
product
especi
interleukin
il
inhibit
phospholipas
therebi
antagon
effect
prostaglandin
absorpt
block
uv
light
cutan
reaction
bind
stabil
dna
inhibit
bcell
receptor
calcium
signal
inhibit
matrix
metalloproteinas
recent
recogn
hcq
also
inhibit
tolllik
receptor
signal
highlight
new
import
effect
might
play
part
numer
pathway
may
contribut
understand
use
mani
autoimmun
diseas
variou
major
known
immunomodulatori
mechan
hcq
schemat
drawn
fig
addit
establish
efficaci
sle
ra
antimalari
also
found
benefici
rheumat
skin
diseas
includ
palindrom
rheumat
discoid
lupu
tradit
indic
use
hcq
summar
tabl
recent
antimalari
shown
potenti
benefici
effect
mani
diseas
includ
diseas
immun
cardiovascular
hematolog
system
well
malign
infecti
diseas
malaria
review
current
evid
novel
applic
antimalari
mainli
chloroquin
hcq
addit
antimalari
effect
hcq
found
effect
bacteri
viral
infect
antibacteri
antivir
effect
attribut
alkalin
hypoglycem
effect
chloroquin
first
demonstr
patient
insulin
resist
later
clinic
trial
noninsulin
depend
diabet
patient
treat
short
cours
chloroquin
exhibit
signific
improv
glucos
toler
patient
hcq
combin
insulin
month
glycat
hemoglobin
decreas
significantli
compar
placebo
insulin
dose
reduc
hcq
group
anoth
studi
diabet
patient
respond
sulfonylurea
success
treat
hcq
glycat
hemoglobin
reduc
presum
antidiabet
mechan
chloroquin
decreas
insulin
clearanc
degrad
rate
increas
secret
cpeptid
although
hcq
shown
hypoglycem
effect
note
current
treatment
option
diabet
mellitu
dm
vari
effect
role
antimalari
diabet
treatment
unlik
use
hcq
may
also
benefici
reduc
cardiovascular
risk
improv
glycem
control
ra
sle
patient
shojania
et
al
describ
case
induct
hypoglycemia
patient
dm
polyarthr
treat
hcq
later
cohort
patient
sle
ra
treatment
hcq
associ
lower
level
fast
blood
glucos
significantli
lower
risk
develop
dm
ra
patient
recent
shown
hcq
significantli
reduc
glycosyl
hemoglobin
diabet
patient
observ
associ
hcq
treatment
lower
risk
dm
rheumat
patient
need
clinic
pharmacolog
studi
assess
hcq
effect
blood
sugar
becom
common
clinic
practic
hydroxychloroquin
also
shown
favor
effect
lipid
profil
patient
rheumat
diseas
wallac
et
al
show
ra
sle
treatment
hcq
lower
level
cholesterol
triglycerid
ldl
irrespect
concomit
steroid
administr
diet
weight
later
studi
confirm
observ
suggest
taken
account
rheumat
patient
signific
cardiovascular
risk
factor
amelior
advers
effect
corticosteroid
therapi
lipid
profil
howev
differ
studi
chines
sle
patient
show
signific
effect
serum
lipid
profil
patient
mild
absent
diseaseact
use
low
corticosteroid
dose
note
addit
metabol
effect
blood
sugar
lipid
hcq
recent
also
shown
improv
endotheli
function
protect
thrombovascular
event
lupu
patient
approxim
year
ago
hcq
shown
prevent
thromboembol
event
patient
go
total
hip
replac
mechan
unknown
time
later
shown
hcq
inhibit
platelet
aggreg
releas
arachidon
acid
stimul
platelet
treatment
hcq
also
shown
protect
thrombosi
lupu
patient
antiphospholipid
syndrom
ap
reduc
risk
plaqu
format
patient
furthermor
hcq
seem
protect
thrombu
format
group
antiphospholipid
apl
antibodi
carrier
without
lupu
antithrombot
mechan
hcq
ap
complet
understood
novel
observ
recent
made
edward
et
al
found
hcq
decreas
thrombu
size
shorten
time
thrombu
clearanc
mice
inject
human
apl
antibodi
recent
espinola
et
al
show
hcq
inhibit
platelet
activ
apl
antibodi
rand
et
al
show
hcq
significantli
reduc
bind
complex
phospholipid
surfac
also
protect
disrupt
potent
anticoagul
annexin
apl
antibodi
vitro
patient
plasma
find
suggest
hcq
integr
part
treatment
ap
especi
patient
concomit
sle
antineoplast
effect
antimalari
first
observ
program
chloroquin
prophylaxi
malaria
tanzania
associ
reduct
incid
burkitt
lymphoma
later
chloroquin
shown
prevent
spontan
lymphoma
develop
mice
model
human
burkitt
lymphoma
ataxia
telangiectasia
suppress
autophagi
induct
cell
death
pathway
hydroxychloroquin
also
shown
induc
apoptosi
malign
bcell
patient
chronic
lymphocyt
leukemia
cll
activ
modul
ratio
recent
biodegrad
nanoparticl
drug
deliveri
system
load
hcq
shown
produc
strong
apoptot
effect
bcll
cell
vitro
except
effect
hematolog
malign
hcq
also
shown
antineoplast
effect
solid
tumor
anti
breastcanc
effect
shown
demonstr
antiprolif
effect
human
breast
tumor
cell
model
antiprolif
effect
mous
colon
cancer
cell
line
shown
well
reduct
tumor
volum
vivo
chloroquin
treatment
chloroquin
also
shown
potenti
antiprolif
effect
human
colorect
cell
line
chloroquin
shown
inhibit
growth
induc
cell
death
lung
cancer
cell
random
doubleblind
placebocontrol
trial
patient
glioblastoma
multiform
treat
chloroquin
much
better
surviv
rate
compar
nontreat
patient
addit
independ
antineoplast
effect
chloroquin
shown
effect
sensit
cancer
cell
radiat
chemotherapi
without
enhanc
normal
cell
vulner
although
preliminari
studi
look
promis
potenti
role
antimalari
treatment
paradigm
malign
still
remain
establish
addit
immunomodulatori
effect
describ
hcq
also
shown
inhibit
cell
respons
foreign
minor
major
histocompat
antigen
therefor
inhibit
develop
graft
versu
host
diseas
gvhd
mice
phase
ii
trial
patient
receiv
bone
marrow
transplant
show
better
gvhd
free
surviv
lower
incid
highgrad
gvhd
patient
treat
hcq
addit
tradit
immunosuppress
drug
howev
phase
iii
trial
fail
exhibit
addit
benefit
gvhd
prevent
hcq
ad
monotherpay
cyclosporin
addit
benefici
effect
hcq
also
shown
anecdot
diseas
hydroxychloroquin
shown
effect
kikuchifujimoto
diseas
benign
diseas
character
lymphadenopathi
fever
usual
occur
young
women
skelet
metabol
effect
sarcoidosi
success
treat
hcq
patient
candid
glucocorticoid
treatment
hydroxychloroquin
enabl
steroid
cessat
patient
subglott
stenosi
steroid
depend
due
edema
granul
tissu
hydroxychloroquin
combin
azathioprin
prompt
major
recoveri
patient
sensori
neuropathi
syndrom
exposur
hcq
pregnanc
mother
sle
carri
antirola
antibodi
associ
decreas
risk
fetal
develop
cardiac
neonat
lupu
compar
mother
treat
hcq
hydroxychloroquin
shown
known
mechan
describ
apl
antiphospholipid
gp
glycoprotein
cll
chronic
lymphocyt
leukemia
gvhd
graft
versu
host
diseas
mhc
major
histocompat
complex
exacerb
psoriasi
enhanc
product
hemoglobin
f
show
therapeut
potenti
hemoglobinopathi
antimalari
contraind
known
hypersensit
patient
histori
retinopathi
taken
proper
dose
chloroquin
extraordinarili
safe
drug
howev
safeti
margin
narrow
singl
dose
mgkg
may
fatal
caution
use
patient
neuromuscular
disord
myasthenia
gravi
patient
psychot
disord
patient
defici
care
monitor
hemolysi
although
extrem
rare
therapeut
dose
acut
chloroquin
toxic
encount
frequent
therapeut
high
dose
administ
rapidli
parenter
rout
toxic
manifest
relat
primarili
cardiovascular
system
central
nervou
system
cn
cardiovascular
effect
includ
hypotens
vasodil
suppress
myocardi
function
cardiac
arrhythmia
eventu
cardiac
arrest
cn
sideeffect
may
includ
confus
convuls
coma
dose
chloroquin
use
oral
therapi
acut
malari
attack
rheumat
skin
diseas
may
caus
gi
upset
headach
visual
disturb
urticaria
pruritu
prolong
use
may
occasion
caus
headach
blur
vision
diplopia
confus
convuls
lichenoid
skin
erupt
bleach
hair
widen
qr
interv
wave
abnorm
complic
rare
usual
disappear
soon
drug
withheld
rare
instanc
hemolysi
blood
dyscrasia
report
chloroquin
may
also
caus
discolor
nail
bed
mucou
membran
irrevers
retinopathi
ototox
result
high
daili
dose
mg
chloroquin
hcq
lead
cumul
total
dose
g
base
per
kilogram
bodi
weight
retinopathi
presum
relat
drug
accumul
melaninrich
tissu
avoid
daili
dose
mg
less
prolong
therapi
high
dose
also
caus
toxic
myopathi
cardiopathi
peripher
neuropathi
reaction
improv
drug
withdrawn
promptli
hydroxychloroquin
cross
placenta
fetu
level
shown
equival
matern
level
howev
fetal
toxic
evid
subsequ
studi
congenit
abnorm
seen
pregnant
patient
treat
hcq
first
trimest
pregnanc
lactat
amount
hcq
transfer
children
seem
low
confer
risk
toxic
child
accordingli
continu
hcq
use
pregnanc
recommend
evid
advic
breastfeed
treatment
summari
antimalari
toxic
main
advers
effect
present
tabl
conclus
sinc
first
use
antimalari
agent
nearli
centuri
ago
effect
diseas
nearli
major
branch
medicin
increasingli
recogn
includ
field
immunolog
oncolog
hematolog
dermatolog
cardiolog
infecti
diseas
summari
effect
antimalari
shown
tabl
date
antimalari
establish
role
treatment
sle
ra
chronic
q
fever
variou
skin
diseas
may
also
role
treatment
antiphospholipid
syndrom
current
mani
ongo
clinic
trial
studi
effect
antimalari
diseas
malign
neoplasm
lung
breast
prostat
pancrea
colon
melanoma
renal
cell
carcinoma
cll
multipl
myeloma
influenza
hiv
infect
osteoarthr
metabol
syndrom
seen
brows
websit
clinicaltrialsgov
mechan
action
hcq
effect
diseas
potenti
condit
still
remain
demonstr
futur
